Novo Nordisk
NVO
#86
Rank
ยฃ152.08 B
Marketcap
ยฃ34.31
Share price
-2.72%
Change (1 day)
-29.12%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): ยฃ3.20

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is ยฃ3.22. In 2025 the company made an earnings per share (EPS) of ยฃ2.66 an increase over its 2024 EPS that were of ยฃ2.45.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)ยฃ3.2020.24%
2025ยฃ2.668.48%
2024ยฃ2.45
2016ยฃ0.84

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
ยฃ0.98-69.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
ยฃ21.14 557.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ1.92-40.41%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
ยฃ2.67-17.12%๐Ÿ‡บ๐Ÿ‡ธ USA